Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil
Adv Rheumatol
;
61: 60, 2021. tab, graf
Artigo
em Inglês
|
LILACS-Express
| LILACS
| ID: biblio-1345107
ABSTRACT
Abstract Background:
There is a lack of information on the role of chronic use of hydroxychloroquine during the SARS-CoV-2 outbreak. Our aim was to compare the occurrence of COVID-19 between rheumatic disease patients on hydroxychloroquine with individuals from the same household not taking the drug during the first 8 weeks of community viral transmission in Brazil.Methods:
This baseline cross-sectional analysis is part of a 24-week observational multi-center study involving 22 Brazilian academic outpatient centers. All information regarding COVID-19 symptoms, epidemiological, clinical, and demographic data were recorded on a specific web-based platform using telephone calls from physicians and medical students. COVID-19 was defined according to the Brazilian Ministry of Health (BMH) criteria. Mann-Whitney, Chi-square and Exact Fisher tests were used for statistical analysis and two binary Final Logistic Regression Model by Wald test were developed using a backward-stepwise method for the presence of COVID-19.Results:
From March 29th to May 17st, 2020, a total of 10,443 participants were enrolled, including 5166 (53.9%) rheumatic disease patients, of whom 82.5% had systemic erythematosus lupus, 7.8% rheumatoid arthritis, 3.7% Sjögren's syndrome and 0.8% systemic sclerosis. In total, 1822 (19.1%) participants reported flu symptoms within the 30 days prior to enrollment, of which 3.1% fulfilled the BMH criteria, but with no significant difference between rheumatic disease patients (4.03%) and controls (3.25%). After adjustments for multiple confounders, the main risk factor significantly associated with a COVID-19 diagnosis was lung disease (OR 1.63; 95% CI 1.03-2.58); and for rheumatic disease patients were diagnosis of systemic sclerosis (OR 2.8; 95% CI 1.19-6.63) and glucocorticoids above 10 mg/ day (OR 2.05; 95% CI 1.31-3.19). In addition, a recent influenza vaccination had a protective effect (OR 0.674; 95% CI 0.46-0.98).Conclusion:
Patients with rheumatic disease on hydroxychloroquine presented a similar occurrence of COVID-19 to household cohabitants, suggesting a lack of any protective role against SARS-CoV-2 infection. Trial registration Brazilian Registry of Clinical Trials (ReBEC; RBR - 9KTWX6).
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
País/Região como assunto:
América do Sul
/
Brasil
Idioma:
Inglês
Revista:
Adv Rheumatol
Assunto da revista:
Artrite
/
Reumatologia
Ano de publicação:
2021
Tipo de documento:
Artigo
País de afiliação:
Brasil
Instituição/País de afiliação:
Fundação de Vigilância Em Saúde Do Amazonas/BR
/
Hospital Geral de Fortaleza/BR
/
Hospital São Paulo da Universidade Federal de São Paulo/BR
/
Hospital Universitário Evangélico Mackenzie/BR
/
Hospital Universitário Getúlio Vargas Universidáde Federal Do Amazonas/BR
/
Hospital Universitário de Brasilia da Universidade de Brasilia/BR
/
Hospital das Clínicas da Universidade Federal de Pernambuco/BR
/
Instituto de Assistência Médica Ao Servidor Público Estadual/BR
/
Instituto de Ensino E Pesquisa No Sírio Libanês/BR
/
Instituto de Medicina Integral Professor Fernando Figueira/BR
Similares
MEDLINE
...
LILACS
LIS